Kyowa KirinKyowa Kirin Co.,Ltd.4151東証プライム医薬品FY ending Dec 2025, consolidated, IFRS
Kyowa Kirin brought in ¥352.2B in revenue.
Out of every ¥100 of sales, about ¥34 is left as operating profit.
Revenue changed +10.6% from the prior year.
FY ending Dec 2020 → FY ending Dec 2021
FY ending Dec 2020 → FY ending Dec 2021
※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains
For every ¥100 Kyowa Kirin sells, how much goes where, and how much is kept.
* This company does not report operating income, so it is calculated as gross profit minus SG&A. Equity-method income and dividends are not included, so net profit can be larger.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
有価証券報告書-第103期(2025/01/01-2025/12/31)
EDINET (FSA Japan)
有価証券報告書-第102期(2024/01/01-2024/12/31)
EDINET (FSA Japan)
有価証券報告書-第101期(2023/01/01-2023/12/31)
EDINET (FSA Japan)
有価証券報告書-第100期(2022/01/01-2022/12/31)
EDINET (FSA Japan)
有価証券報告書-第99期(令和3年1月1日-令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書-第98期(令和2年1月1日-令和2年12月31日)
Extracted from XBRL: 42 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.